Kingdom of Saudi Arabia – The Middle East Healthcare Company “Saudi German Healthcare”, one of the largest healthcare groups in the Kingdom of Saudi Arabia, held its Ordinary General Assembly meeting, which witnessed the adoption of a number of strategic and financial decisions.

The decisions included adopting the Board of Directors’ report and financial statements for the fiscal year ending in 2025 , along with approving the distribution of cash dividends worth 46.02 million Saudi Riyals, at a rate of 0.50 Riyals per share, equivalent to 5 percent of the nominal value of the share .

The meeting also saw the election of a new board of directors for the term extending from 2026 to 2030 , thus supporting the diversity of expertise and the board's independence. Shareholders also approved the appointment of an external auditor for the fiscal year 2026 and the first quarter of 2027 , in addition to discharging the board members from liability for the fiscal year 2025 and approving the payment of board bonuses amounting to SAR 1.36 million for the same year .

The decisions adopted by the General Assembly, foremost among them the election of a new Board of Directors comprising a majority of independent members and a selection of diverse practical expertise in various fields, embody the Board's ability to formulate ambitious strategic plans and support well-considered decisions to achieve sustainable growth based on governance, transparency and operational efficiency .

The new board of directors brings together a diverse mix of expertise from the healthcare, investment, finance, business, academic, and legal sectors across the Kingdom, enhancing the group's ability to keep pace with the rapid changes in the healthcare sector at both the local and regional levels. Furthermore, the strategic decisions made by the board support the corporate governance framework, a move that promotes continued growth and improves the efficiency of decision-making.

In this context, Dr. Nizar Bahabri, CEO of Saudi German Healthcare, stated : “The results of the General Assembly and its approval of the distribution of profits and the election of a new Board of Directors represent an important milestone in the journey of our long-established institution, and reflect the confidence of our shareholders in the strength of the Group’s business model and its ability to achieve sustainable and balanced growth and create long-term value for shareholders. Over the past years, we have worked to establish strong foundations for growth by developing the governance system, enhancing operational efficiency, expanding the scope of specialized services, and investing in national and high-quality medical talent . ”

Dr. Bahabri added: “We view the next phase as a qualitative transformation based on the deliberate expansion of specialized care, the development of centers of excellence, accelerating the pace of digital transformation and health innovation, and enhancing the localization of medical competencies, which contributes to supporting the objectives of the Kingdom’s Vision 2030 and consolidates the position of Saudi German Health as a key partner in developing the healthcare system in the Kingdom and the region.”

In detail, the new Board of Directors includes members representing various regions of the Kingdom, in a step that contributes to meeting the aspirations of the Saudi health community and enhances the prosperity of the group. They are: Abdul Aziz Hashim Ashwi Al-Anzi, Dr. Ahmed Abdullah Ahmed Al-Ali, Dr. Abdul Karim Hamad Abdul Karim Al-Najidi, Dr. Farid Ahmed Mohammed Khouqir, Mater Saud Hatilan Al-Anzi, Niklas Jarimu, and Dr. Osama Sadiq Abdul Rahman Tayeb.

On another note, the newly elected board of directors will hold its first meeting to elect its chairman and vice-chairman, form its subcommittees, and distribute tasks and responsibilities in accordance with the Companies Law, the Capital Market Authority's regulations, and the company's articles of association . This will be within the scope of the powers delegated to it by the general assembly for a one-year term, in accordance with relevant laws and regulatory instructions. The results of the meeting will be announced in due course through official channels.

It is worth noting that Saudi German Healthcare has continued over the past two years to implement its growth strategy, by attracting more than 700 doctors and professionals with subspecialties and sub-specialties, including 440 Saudis, and developing 13 centers of excellence in advanced medical fields, in addition to strengthening its strategic partnership with Mayo Clinic, which supports the objectives of the next phase in raising the quality of healthcare, enhancing the patient experience, and achieving sustainable value for shareholders.

For more information or media inquiries, please contact us via email at: Saudigermanhealth@four.agency.com

-I finish-

#Company Data

Disclaimer regarding the content of press releases
The content of this press release is provided by a third-party provider. We do not assume any responsibility for, nor do we have any control over, such content. This content is provided on an "as is" and "as available" basis and is not edited in any way. Neither we, nor our affiliates, will be liable for the accuracy, endorsement, or completeness of any opinions, views, information, or materials contained in this content.
This press release is provided for informational purposes only; the content does not constitute legal, investment, or tax advice, nor does it offer any opinion on the suitability, value, or profitability of any particular portfolio or investment strategy. Neither we nor our affiliates will be liable for any errors or inaccuracies in the content, or for any actions you take based on that content. You expressly agree and acknowledge full responsibility for your use of the information contained in this press release.
To the extent permitted by applicable law, Refinitiv, its parent company, subsidiaries, affiliates, relevant shareholders, directors, officers, employees, agents, advertisers, content providers, and licensors (collectively, the 'Refinitiv Parties') shall not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive, or exemplary damages; This includes, but is not limited to, losses of profits, savings, or revenues, whether due to negligence, tort, contract, or other theories of liability, even if the parties to Refinitiv were advised of the possibility of any such damages or losses occurring or actually anticipated them.